In May 2026, reporting on FDA clearance described the ACIST Pro Diagnostic System—a variable-rate contrast management platform for image-guided interventional cardiology—from ACIST Medical Systems and Bracco Imaging. Public materials highlighted real-time contrast tracking, customizable dose targets, and design updates that may reduce setup time compared with the prior ACIST CVi platform, along with published experience on contrast use and case efficiency in cath lab workflows.
For cardiovascular device sales professionals, contrast and imaging adjunct technologies are part of the economic story hospitals track: procedure time, contrast volume, and kidney-risk stewardship increasingly influence purchasing conversations alongside clinical outcomes.
Why Cath Lab Reps Should Pay Attention
- Workflow efficiency claims must be validated in live lab workflows—not slide decks alone
- Contrast stewardship aligns with hospital quality metrics and cost scrutiny
- Cross-functional selling spans interventional cardiology, radiology, and supply chain
- Technicians and nurses often influence adoption as much as attending physicians
Hiring and Territory Notes
Employers hiring “cardio device” reps should specify whether the role covers implants, adjunct systems, or a portfolio mix. Candidates with cath lab presence—case support, inventory fluency, and lab technician relationships—translate better than pure office-based pharma backgrounds.